Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 5/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CD38 | P28907 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084369 | 1.00 | KAT2B (0.56) | KAT2BRAB9ANPC1CNR2CNR1 | |
| SCHEMBL19701302 | 0.87 | RAB9A (0.51) | RAB9ACNR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL23575920 | 0.87 | RAB9A (0.51) | RAB9ACNR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL22449379 | 0.86 | HIF1A (0.56) | RAB9ANPC1ACKR3 | |
| SCHEMBL23575894 | 0.83 | SMYD3 (0.61) | RAB9ACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL19701301 | 0.83 | SMYD3 (0.61) | RAB9ACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL7391725 | 0.80 | ALDH1A1 (0.63) | CHRNB2CHRNA4 | |
| SCHEMBL3125620 | 0.80 | RAB9A (0.49) | RAB9ANPC1CNR2CNR1CHRNB2 | |
| SCHEMBL7399990 | 0.78 | HTR3A (0.64) | CHRNB2CHRNA4 | |
| SCHEMBL14428750 | 0.77 | CHRNB2 (0.46) | RAB9ACHRNB2CHRNA7CHRNA4ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1595871-A2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| EP-1196397-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2000073283-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | KAT2B 1940/4885RAB9A 1751/4885NPC1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.